Skip to content

Maraviroc improves liver fibrosis in HIV/hepatitis C co-infected patients

Maraviroc improves liver fibrosis in HIV/hepatitis C co-infected patients

With special training, effective and safe hepatitis C therapy can be provided in primary care

Project ECHO care teams take part in a virtual care conference using teleconferencing to link remote primary care centres to the University of New Mexico

Coffee drinking improves hepatitis C treatment response rate in mono-infected patients

HIV-positive patients who receive therapy for acute HCV can be cured with just 24 weeks of therapy

US approval for hepatitis C drug telaprevir

European approval recommended for hepatitis C drug boceprevir

Genetic variation associated with response to hepatitis C therapy in HIV co-infected patients

HIV treatment preserves CD4 cell count during and after HCV therapy in co-infected patients

Twice-weekly pegylated interferon improved early treatment responses in co-infected patients